Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Amy Young · SciRah

Researcher profile · Semantic Scholar

Amy Young

Share profile

Amy Young — researcher profile on SciRah

h-index: 18
Works: 35
Citations: 2,272

Most-cited papers

Therapeutic strategies for targeting ras proteins.
Stephan Gysin, Megan Salt, Amy Young, F. McCormick
2011Genes & cancer325 citations Open access
Semantic Scholar
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
E. Punnoose, J. Leverson, F. Peale, E. Boghaert +16 more
2016Molecular Cancer Therapeutics286 citations Open access
Semantic Scholar
Single-cell dynamics determines response to CDK4/6 inhibition in triple negative breast cancer
U. Asghar, Alexis R. Barr, R. Cutts, M. Beaney +10 more
2017Clinical Cancer Research231 citations Open access
Semantic Scholar
Ras signaling and therapies.
Amy Young, J. Lyons, Abigail L. Miller, V. Phan +2 more
2009Advances in Cancer Research211 citations
Semantic Scholar
Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.
Amy Young, David Y. Lou, F. McCormick
2013Cancer Discovery207 citations Open access
Semantic Scholar
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility.
Jane Guan, W. Zhou, M. Hafner, R. Blake +25 more
2019Cell193 citations Open access
Semantic Scholar
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence In Cancer
M. R. Burgess, E. Hwang, R. Mroue, C. Bielski +18 more
2017Cell163 citations Open access
Semantic Scholar
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.
Emily J. Hanan, Marie-Gabrielle Braun, R. Heald, Calum Macleod +31 more
2022Journal of Medicinal Chemistry129 citations Open access
Semantic Scholar
GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.
Jun Liang, J. Zbieg, R. Blake, Jae H. Chang +43 more
2021Journal of Medicinal Chemistry118 citations Open access
Semantic Scholar
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
J. Joseph, B. Darimont, Wei Zhou, Alfonso Arrazate +42 more
2016eLife96 citations Open access
Semantic Scholar
Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors.
S. Staben, Jian-Wen A. Feng, Karen S. Lyle, M. Belvin +20 more
2014Journal of Medicinal Chemistry61 citations Open access
Semantic Scholar
Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition
D. Kirkpatrick, D. Bustos, Taner Dogan, J. Chan +7 more
2013Proceedings of the National Academy of Sciences of the United States of America53 citations Open access
Semantic Scholar
Systems-wide Analysis of K-Ras, Cdc42, and PAK4 Signaling by Quantitative Phosphoproteomics*
Florian Gnad, Amy Young, Wei Zhou, Karen S. Lyle +8 more
2013Molecular & Cellular Proteomics48 citations Open access
Semantic Scholar
Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors
K. Z. Zimmerman Savill, Brian B. Lee, J. Oeh, Jie Lin +18 more
2022Nature Communications32 citations Open access
Semantic Scholar
Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.
Jun Liang, R. Blake, Jae H. Chang, L. Friedman +29 more
2020ACS Medicinal Chemistry Letters26 citations Open access
Semantic Scholar
Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies
Rebecca Hong, K. Edgar, Kyung Song, S. Steven +12 more
201821 citations Open access
Semantic Scholar
Abstract P5-04-07: GDC-9545: A novel ER antagonist and clinical candidate that combines desirable mechanistic and pre-clinical DMPK attributes
C. Metcalfe, E. Ingalla, R. Blake, Jae H. Chang +20 more
2019Poster Session Abstracts20 citations
Semantic Scholar
Role of the E3 ubiquitin ligase RNF157 as a novel downstream effector linking PI3K and MAPK signaling pathways to the cell cycle
Taner Dogan, Florian Gnad, J. Chan, L. Phu +9 more
2017Journal of Biological Chemistry19 citations Open access
Semantic Scholar
Abstract 156: Preclinical characterization of GDC-0077, a specific PI3K alpha inhibitor in early clinical development
K. Edgar, Emily J. Hanan, S. Staben, S. Schmidt +10 more
20179 citations
Semantic Scholar
86OPI3 kinase/mTOR inhibition increases sensitivity of ER positive breast cancers to CDK4/6 inhibition by blocking cell cycle re-entry driven by cyclinD1 and inducing apoptosis
M. T. Herrera-Abreu, U. Asghar, R. Elliot, A. Pearson +6 more
20159 citations Open access
Semantic Scholar
Abstract S6-04: The PI3K inhibitor, taselisib, has enhanced potency in PIK3CA mutant models through a unique mechanism of action
L. Friedman, K. Edgar, Kyung Song, S. Schmidt +8 more
20167 citations
Semantic Scholar
Abstract 146: The PI3K inhibitor, taselisib, has a unique mechanism of action that leads to enhanced potency in PIK3CA mutant models
Kyung Song, K. Edgar, D. Kirkpatrick, L. Phu +8 more
20174 citations
Semantic Scholar
Abstract 3406: GDC-9545: A pure antiestrogen clinical candidate that immobilizes the estrogen receptor and profoundly alters chromatin accessibilityin vivo
C. Metcalfe, Wei Zhou, Jane Guan, R. Blake +13 more
2020Cancer Chemistry3 citations
Semantic Scholar
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
J. Joseph, B. Darimont, Wei Zhou, Alfonso Arrazate +42 more
2019eLife2 citations Open access
Semantic Scholar
Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers.
Wei Zhou, Musaddeque Ahmed, Jane Guan, Natalie S. Fox +16 more
2026Cell Chemical Biology1 citations Open access
Semantic Scholar
Abstract GS3-05: Prospective optimization of estrogen receptor degradation yields ER ligands with variable capacities for ER transcriptional suppression
C. Metcalfe, Wei Zhou, Jane Guan, A. Daemen +14 more
2019General Session Abstracts1 citations
Semantic Scholar
Abstract 1648: Discovery and evolution of orally bioavailable selective estrogen receptor degraders for ER+ breast cancer: From GDC-0810 to GDC-0927
M. Kahraman, S. Govek, J. Nagasawa, Andiliy G. Lai +37 more
2018Cancer Chemistry1 citations
Semantic Scholar
Abstract 2672: Characterization of the enhanced potency of PI3K inhibitor taselisib (GDC-0032) in PI3K mutant cell lines and models
K. Edgar, M. Nannini, Rebecca Hong, C. Eigenbrot +5 more
20151 citations
Semantic Scholar
Abstract 4998: Selective PLK4 inhibition demonstrates synthetic lethality in TRIM37 amplified neuroblastoma and breast cancer models while less selective inhibitors do not
S. McRee, Chelsea Chen, C. Colas, Wie Fang +15 more
2023Cancer Research0 citations
Semantic Scholar
Abstract 2633: Discovery of novel, highly selective inhibitors of PLK4 that demonstrate in vivo regressions in TRIM37 high xenografts
K. Edgar, Amy Young, Jared Moore, Xi Chen +12 more
2022Cancer Research0 citations
Semantic Scholar
Abstract P2-11-05: ER pathway activity signature as a biomarker for endocrine agent GDC-9545
A. Daemen, J. Spoerke, Wei Zhou, Jane Guan +16 more
2020Poster Session Abstracts0 citations
Semantic Scholar
Abstract B36: Progesterone receptor signaling in estrogen receptor-positive breast cancer
Amy Young, Jane Guan, A. Daemen, L. Friedman +1 more
2018Resistance Mechanisms0 citations
Semantic Scholar
Abstract P5-04-01: Cell cycle dynamics at single cell level dictates response to CDK4/6 inhibition
U. Asghar, Alexis R. Barr, R. Cuts, M. Beaney +10 more
20170 citations
Semantic Scholar
Abstract P4-06-05: Treatment ofESR1mutant andPIK3CAmutant patient-derived breast cancer xenograft models reveals differential anti-tumor responses to estrogen receptor degraders and PI3K inhibitorsin vivo
Amy Young, Lisa M. Crocker, Eric Cheng, J. Lacap +10 more
20170 citations
Semantic Scholar
Regulation of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling by wild-type and oncogenic Ras
Amy Young
20110 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Friedman×22
Invite
L. Friedman — researcher profile on SciRah
D. Sampath×21
Invite
D. Sampath — researcher profile on SciRah
M. Nannini×15
Invite
M. Nannini — researcher profile on SciRah
E. Ingalla×13
Invite
E. Ingalla — researcher profile on SciRah

×11

Invite

J. Giltnane — researcher profile on SciRah

C. Metcalfe×11

Invite

C. Metcalfe — researcher profile on SciRah

Invite

R. Blake — researcher profile on SciRah

Invite

A. Daemen — researcher profile on SciRah

Invite

J. Oeh — researcher profile on SciRah

Invite

Jane Guan — researcher profile on SciRah

Invite

K. Edgar — researcher profile on SciRah

Xiaojing Wang×7

Invite

Xiaojing Wang — researcher profile on SciRah